Results 161 to 170 of about 50,706 (199)

Multi-centric origins and gene flow shape the diversity of β-thalassemia mutations in Southern East Asia. [PDF]

Nat Commun
Zhang Q, Li J, Huang H, Shang X, Ye Y, Zhang W, Lin P, Gong Y, Hoh BP, Luo Q, Yan T, Pan X, Stoneking M, Xu S, Xu X, Deng L.   +15 more
europepmc   +1 more source

Assessment of β-Thalassemia Trait Occurrence in an Outpatient Sample from Southern Chile: A Retrospective Study. [PDF]

Diagnostics (Basel)
Balcázar-Villarroel M, Mancilla-Uribe A, Navia-León S, Carrasco-Fajardin L, Bohle-Matamala J, Calbucura-Ovalle C, Torrens F, Carmine-Peña E, Sandoval C, Peña F.   +9 more
europepmc   +1 more source

Luspatercept versus mitapivat for non-transfusion-dependent β-thalassemia: Dare to compare? [PDF]

Hemasphere
Musallam KM, Sheth S, Cappellini MD, Kuo KHM, Kattamis A, Aydinok Y, Viprakasit V, Taher AT.   +7 more
europepmc   +1 more source

Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study. [PDF]

Blood Adv
Taher AT, Viprakasit V, Kattamis A, Perrotta S, Ricchi P, Porter JB, Coates TD, Forni GL, Musallam KM, Esposito O, Pilot R, Kuo WL, Lai Y, Reverte M, Wei R, Bueno LM, Cappellini MD.   +16 more
europepmc   +1 more source

Luspatercept in Transfusion-Dependent β-Thalassemia: The Benefit Is Real, and So Are the Risks. [PDF]

Am J Hematol
Musallam KM.
europepmc   +1 more source

Luspatercept Treatment in a β-Thalassemia Patient with Pulmonary Arterial Hypertension: A Case Report. [PDF]

Mediterr J Hematol Infect Dis
Yang B, Liu D, Yang C, Zhou Y, Liao G, Huang J, Li Y, Tang Y, Yin X.   +8 more
europepmc   +1 more source

Are Mitochondria a Potential Target for Treating β-Thalassemia? [PDF]

J Clin Med
Di Pierro E, Di Stefano V, Migone De Amicis M, Graziadei G.   +3 more
europepmc   +1 more source

Causes of hospital admission in β-thalassemia (CHAT) in Lebanon from 1995 to 2015: A pilot retrospective study from a tertiary care center [PDF]

, 2017
Beydoun, Hassan, Bou-Fakhredin, Rayan, Harb, Afif, Moukhadder, Hassan M., Saliba, Antoine N., Taher, Ali T.   +5 more
core   +1 more source

β-thalassemia trait and iron overload: is it time to consider oral iron chelators? Comment on: "A case series of patients with β-thalassemia trait and iron overload: from multifactorial hepcidin suppression to treatment with mini-phlebotomies". [PDF]

Haematologica
Piperno A, Mariani R.
europepmc   +1 more source

TIF Guidelines for the Management of Transfusion-Dependent β-Thalassemia. [PDF]

Hemasphere
Musallam KM, Cappellini MD, Porter JB, Farmakis D, Eleftheriou A, Angastiniotis M, Taher AT.   +6 more
europepmc   +1 more source